Skip to main content
. 2019 Dec 11;9(12):e031019. doi: 10.1136/bmjopen-2019-031019

Table 2.

Pembrolizumab plus chemotherapy cost-effectiveness at additional modelled price points

Parameter Base case model analysis*
WTP value, $/QALY 100 000 15 000
Nivolumab cost, $/mg 12.05 31.38
Total cost, $ 176 197 235 651
QALYs 1.61 1.61
ICER, $/QALY 99 915 149 907

*Only the cost of pembrolizumab was varied.

ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year; WTP, Willingness-to-pay.